Our Mission

We are a division of CobiCure, a pediatrics-focused nonprofit company within Advancium Health Network, committed to bringing life-changing therapeutics to patients by utilizing philanthropic funding and strategic partnerships. We manage a portfolio of projects addressing high-impact needs in the underserved markets of pediatrics and rare diseases.

Pediatric cancers and rare diseases are underfunded and underserved:

More than 300M children worldwide suffer from a rare disease. ¹
95% of rare diseases do not have approved treatments. ²
30% of children with a rare disease won’t live to see their fifth birthday. ³

Source
1 - www.rarediseaseday.org
2 & 3 - www.rarediseases.org

We are building an accelerator to deliver life-changing products to children by:

In-licensing, acquiring or co-developing therapeutic assets that will reduce patient morbidity and mortality

Partnering with leading experts and funders with similar goals to leverage exceptional skills and resources

Advancing assets through late-stage R&D, clinical trials, and regulatory clearance/approval

Help us Make an Impact

We are seeking funders and collaborators to advance our mission. How you can help:

Make a financial contribution to support our work
Connect us to drug development programs aligned with our mission
Share your expertise

News at CobiCure Therapeutics

CobiCure Therapeutics Launches to Develop New Medicines for Pediatric Cancers and Rare Diseases

August 7, 2025 | New nonprofit endeavor will focus on accelerating promising therapies that would otherwise be overlooked by traditional biotech funders

Frankel Foundation Ignites $10 Million Accelerator at CobiCure for Pediatric Clinical Development

July 30, 2025 | Landmark investment establishes dedicated accelerator to fast-track life-saving innovations to accelerate clinical development for pediatric medical devices and therapies for childhood cancer and rare diseases

Changing the Business Model for Pediatric Rare Diseases CobiCure’s Mission: Overcoming Barriers to Deliver Effective Treatments to Children Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma Real Stories: Why CobiCure’s Mission Matters to Our CEO, Mark Veich